The use of unfractionated heparin and low molecular weight heparins in pregnancy

Clinical Obstetrics and Gynecology

Volumn 49, Issue 4, 2006, Pages 895-905

  Casele, Holly L ^a  

^a San Diego Perinatal Center   (United States)

Author keywords

Low molecular weight heparin; Pregnancy; Unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ARDEPARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PENTASACCHARIDE; REVIPARIN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTITHROMBIN III DEFICIENCY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HEART VALVE PROSTHESIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTRAPARTUM CARE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PREGNANCY; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OSTEOPOROSIS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRIMARY PREVENTION; THROMBOCYTOPENIA;

EID: 33750616386     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000211958.45874.63     Document Type: Review

References (58)

1. Ginsberg JS, Kowalchuk G, Hirsch J, et al. Heparin therapy during pregnancy: risks to the fetus and the mother. Arch Intern Med. 1989;149:2233-2236.
2. Ginsberg JS, Hirsch J, Turner C, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost. 1989;61:197-203.
3. ACOG Practice Bulletin No. 19, Thromboembolism in Pregnancy. Washington DC; August 2000.
4. Basu D, Gallus A, Hirsch J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;279:324-327.
5. Chiu HM, Hirsch J, Yung WL, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
6. Casele HL, Laifer SA. Hemorhagic complication of anticoagulation during pregnancy in a woman with lupus anticoagulant. Obstet Gynecol. 1997;90(4 Pt 2):646-647.
7. Hirsh J. Drug Therapy. NEJM. 1991;234:1565-1574.
8. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
9. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:627S-644S.
10. Bergqvist D, Matzch T, Bergqvist A, et al. Recurrent thromboemboism in pregnancy and puerperium. Am J Obstet Gynecol. 1985;28:107-118.
11. Ginsberg JS, Brill-Edwards P, Burrows RF, et al. Venous thrombosis during pregnancy; leg and trimester of presentation. Thromb Haemost. 1992;67:519-520.
12. Rutherford S, Monotoro M, McGehee W, et al. Thromboembolic disease associated with pregnancy: an 11 year review (abstract). Am J Obstet Gynecol. 1991;164:286.
13. Bergqvist A, Bergqvist D, Holbrook T. Deep vein thrombosis during pregnancy: a prospective study. Acta Obstet Gynecol Scand. 1983;62:443-448.
14. Buller HR, Agnelli G, Hull R, et al. Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP Conference on Antithrombotic and thrombolytic therapy. Chest. 2004;126:401S-428S.
15. Weiner CP. Diagnosis and management of thromboembolic disease in pregnancy. Clin Obste Gynecol. 1985;28:107-118.
16. Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism thromboprophylaxis during pregnancy. Am J Obstet Gynecol. 1995;173:1869-1873.
17. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism in pregnancy and puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obste Gynecol. 1993;168:1265-1270.
18. Dahlman TC, Hellgren MSE, Blomback M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol. 1989;161:402-405.
19. Brancazio LR, Roperti KA, Stierer R, et al. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol. 1995;173:1240-1245.
20. Losito R, Losito C. Molecular weight of heparin versus biological activity. Semin Thromb Hemostasis. 1985;11:29-33.
21. Fareed J, Jeske W, Hoppensteadt D, et al. Are the available low molecular weight heparin preparations the same? Semin Thromb Hemostasis. 1996;22(suppl 1):77-91.
22. Laurent P, Dussarat G, Bonal J, et al. Low molecular weight heparins: a guide to their optimum use in pregnancy. Drugs. 2002;62:463-477.
23. Omri A, Dellaloye JF, Anderson H, et al. Low molecular weight heparin novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost. 1989;1:55-56.
24. Dimitrakakis C, Papgeorgiou P, Papageorgiou I, et al. Absence of transplacental passage of low molecular weight heparin enoxaparin. Haemostasis. 2000;30:243-248.
25. Harenberg J, Schneider D, Heilman L, et al. Lack of anti-factor Xa activity in umbilical cord vein samples after subcuataneous administration of heparin or low molecular weight heparin in pregnant women. Thromb Haemost. 1993;23:314-320.
26. Weitz JI. Low molecular weight heparins. NEJM. 1997;337:688-698.
27. Harenberg J, Wurzener B, Zimmermann R, et al. Bioavailability and antagonization of the low molecular weight heparin CY216 in man. Thromb Res. 1986;44:549-554.
28. Casele HL, Laifer SA, Woelker DA. Venkataramanan Changes in the pharmokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181:1113-1117.
29. Gould MK, Dembitzer AD, Doyle RL, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1999;130:800-809.
30. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low molecular weight heparin versus standard heparin in general and orthopedic surgery: a metaanalysis. Lancet. 1992;340:152-156.
31. Dolovich L, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low molecular weight heparins to unfractionated heparin in the treatment of venous thromboembolism examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Intern Med. 2000;160:181-188.
32. Pettila V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96:275-282.
33. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment and deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis. 1986;16(Suppl 2):30-37.
34. Faivre R, Neuhart E, Kieffer Y, et al. Subcutaneous administration of low molecular weight heparin CY 222 compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. (Abstr) Thromb Haemost. 1987;58(suppl):430.
35. Bratt G, Tornebohm E, Granqvist S, et al. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep vein thrombosis (DVT). Thromb Haemost. 1985;54:813-817.
36. Bratt G, Aberg W, Johansson M, et al. Two daily subcutaneous injection of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost. 1990;64:506-510.
37. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med. 1992;326:975-982.
38. Duroux P, Beclere A. A randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1991;65:251-256.
39. Simmoneau G. Subcutaneous fixed dose of enoxaparin versus intravenous adjusted dose of unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost (Abstr). 1991;65(suppl):754.
40. Prandoni P, Lensing AWA, Buller HR, et al. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992;339:441-445.
41. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis. A Polish ulitcenter Trial. Thromb Haemost. 1992;68:14-18.
42. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med. 1995;155:601-607.
43. Hirsh J. Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Semin Thromb Hemost. 1996;22(suppl 2):7-11.
44. Hague WM, North RA, Gallus AS, et al. Anticoagulation in pregnancy and puerperium. Med J Aust. 2001;175:258-263.
45. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
46. Lovenox Injection (package insert). Aventis Pharamceuticals; 2002.
47. ACOG Committee Opinion. Safety of Lovenox in Pregnancy. Washington, DC; 2002:276.
48. Anticoagulation in Prosthetic Heart Valves in Pregnancy Consensus Report (APPCR). Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Clin Cardiol Consensus Rep. 2002;3:1-20.
49. Griffith GC, Nichols G Jr, Asher JD, et al. Heparin osteoporosis. JAMA. 1965;193:915.
50. Dahlman T. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265-1270.
51. Dahlman TC, Sjoberg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315-1320.
52. Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obste Gynecol. 1994;170:862-869.
53. Matzsch T, Bergqvist D, Hedner U, et al. Effects of low molecular weight heparin and unfractionated heparin on induction of osteoporosis in rats. Thromb Haemost. 1990;63:505-509.
54. Monreal M, Vinas L, Monreal L, et al. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and low molecular weight heparin. Haemost. 1990;20:204-207.
55. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin effect on bone density. Thromb Haemost. 1990;64:286-289.
56. Casele HL, Laifer SA. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Maternal Fetal Medicine. 2000;9:122-125.
57. Casele H, Haney E, James A, et al. Bone Density Changes in Women Receiving Thromboprophyalxis in Pregnancy. Am J Obstet Gynecol. 2005;193:S14.
58. Casele H, Haney E. Bruising in women undergoing thromboprophylaxis in pregnancy. Am J Obstet Gynecol. 2005;193:S81.